Stanford and University of Illinois Chicago ACE-D Study (ACE-D)

ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial

The purpose of this study is to understand how a psychotropic medication called guanfacine affects brain network functioning in humans, and how this function interacts with cognitive impairments in people experiencing depressive symptoms.

Study Overview

• Status: Not yet recruiting
• Conditions: Depression
• Intervention / Treatment: Drug: Guanfacine; Drug: Sertraline

Detailed Description

The investigators will conduct a parallel-group, double-blind randomized trial at Stanford Bay Area and Chicago sites, identifying 160 participants across Stanford University and the University of Illinois Chicago with a prominent clinical cognitive signature (C+) and relative absence of the signature (C-).

If you are eligible and choose to participate based off of your answers on the screening survey, the investigators will call you on the number you have provided to verify participants' responses and answer any additional questions you may have about the study.

The first screening visit will consist of obtaining participants' informed consent to participate in the study, completing cognitive testing, answering questions about participants' thoughts and feelings, and providing information about participants' medical and psychiatric history. In addition, this initial screening visit will consist of undergoing an EKG with a medical professional.

If participants are deemed eligible at this phase, the investigators will ask participants to come in for another in-person visit (3 hours) that would involve a non-invasive brain scan. If a participant Is eligible, they will be randomized to receive guanfacine plus sertraline or placebo plus sertraline for an 8 week treatment phase.

Starting week 1 and for every other week during the 8-week treatment phase, participants will complete surveys, passive sampling with the BiAffect application, and conduct cognitive testing. Additionally, starting week 2 and every other week thereafter, participants will conduct a virtual or in-person physician visit. At the end of week 8, the investigators will conduct an MRI visit that resembles the initial MRI visit. Participants will be unblinded over weeks 9-10 to arrange for the participants transition out of the trial.

• Study Type: Interventional
• Enrollment (Estimated): 160
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Leyla Boyar, BA; Phone Number: 6504989326; Email: ljboyar@stanford.edu

Study Locations

• United States
  • California
    • Palo Alto, California, United States, 94305
      • Stanford Psychiatry and Behavioral Sciences Department
  • Illinois
    • Chicago, Illinois, United States, 60607
      • University of Illinois at Chicago
      • Contact: Jun Ma, PhD
      • Principal Investigator: Jun Ma, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

• 18-60 years of age
• Meets DSM-5-TR diagnostic criteria for current, past, or recurrent nonpsychotic MDD established via the participant's medical record and confirmed with using the Mini International Neuropsychiatric Interview (MINI Plus) when the diagnosis is not clear in the medical record
• At least moderately severe depression as defined as a score of 10 or higher on the PHQ-9
• Meets criteria for cognitive impairment (<=-.5 standard deviation below healthy norms) or intact cognition (within healthy range) subgroups based on a computerized behavioral tests of cognitive control performance (WebNeuro) relative to healthy norms
• Usual treating physician support for participation in the study (including that patients currently on psychotropics who can be safely tapered may be tapered off to participate but must wait at least 5 half-lives prior to first scan);
• Fluent and literate in English; and g) written informed consent.

Exclusion Criteria.

• Suicidal ideations representing imminent risk, defined by a score of ≥ 8 on the MINI Plus, or by clinician judgement
• History of a DSM-5 bipolar disorder (I, II, not otherwise specified) or psychosis (current or lifetime) established via the participant's medical record and confirmed using the MINI Plus as necessary
• History of DSM-5 alcohol or substance use disorder in the last 6 months established via the participant's medical record and confirmed using the MINI Plus as necessary
• Current DSM-5 PTSD, OCD, ADHD, and/or ED established via the participant's medical record and confirmed using the MINI Plus as necessary
• Current or lifetime history of medical illness or brain injury that may interfere with assessments
• Severe impediment to vision, hearing, and/or hand movement, likely to interfere with protocols
• Pregnant, breastfeeding, or unwilling or unable to use adequate birth control throughout the study
• 3.0T MRI scanner contraindications
• Concurrent participation in other intervention studies
• Current use of psychotropic medications contraindicated by GIR or the standard antidepressant medication, sertraline, to which subjects could be randomized
• Prior inadequate response sertraline or guanfacine
• General medical condition or disorder that is deemed by study physicians to be unsafe for GIR as reported by patient or found on medical screening (i.e., kidney or liver impairment, hypotension as defined by SBP ≤ 90 and/or DBP ≤ 60 and/or bradycardia as defined by HR ≤ 55 on 2 of 3 separate measurements at least 5 minutes apart, history of syncope, EKG abnormalities, or family history of cardiac events)
• Positive drug screen for any substance deemed by the study physician to be unsafe for use with GIR in combination with other screening information
• Current use of a strong CYP3A4 inhibitor or inducer.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Guanfacine + Placebo; We will conduct a parallel-group, double-blind randomized trial at Stanford Bay Area and Chicago sites, identifying 160 participants with a prominent clinical cognitive signature (C+) and relative absence of the signature (C-). We will enrich for C+, the signature of interest, at a 2:1 ratio. Participants will be randomly assigned to receive guanfacine (shown to ameliorate cognitive control deficits in our preliminary data) plus sertraline or placebo plus sertraline.	Drug: Guanfacine; Guanfacine immediate release is an established and safe FDA-approved treatment that acts directly by stimulating α2A adrenoceptors.
Experimental: Sertraline + Placebo; We will conduct a parallel-group, double-blind randomized trial at Stanford Bay Area and Chicago sites, identifying 160 participants with a prominent clinical cognitive signature (C+) and relative absence of the signature (C-). We will enrich for C+, the signature of interest, at a 2:1 ratio. Participants will be randomly assigned to receive guanfacine (shown to ameliorate cognitive control deficits in our preliminary data) plus sertraline or placebo plus sertraline.	Drug: Sertraline; Sertraline is a well-tolerated FDA-approved antidepressant that is among the most widely prescribed medications for depression.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Remission of depressive symptoms	A score of <=5 on the PHQ-9	8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in disability	Score on the Sheehan Disability Scale which ranges from 0 to 30	8 weeks
Change in quality of Life	Score on the Short Form 8 Health Survey (SF-8) which ranges from 0 to 100	8 weeks

Collaborators and Investigators

• Sponsor: Stanford University
• Investigators: Principal Investigator: Leanne Williams, PhD, Stanford University

Study record dates

Study Major Dates

• Study Start (Estimated): February 1, 2026
• Primary Completion (Estimated): October 1, 2028
• Study Completion (Estimated): February 1, 2029

Study Registration Dates

• First Submitted: May 6, 2024
• First Submitted That Met QC Criteria: May 8, 2024
• First Posted (Actual): May 10, 2024

Study Record Updates

• Last Update Posted (Actual): May 10, 2024
• Last Update Submitted That Met QC Criteria: May 8, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Depression; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic Agonists; Psychotropic Drugs; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Serotonin Agents; Antidepressive Agents; Selective Serotonin Reuptake Inhibitors; Sertraline; Guanfacine
• Other Study ID Numbers: 75568

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes